We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

6 hedge funds and large institutions have $965K invested in Seelos Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% less funds holding

Funds holding: 10 → 6 (-4)

50% less funds holding in top 10

Funds holding in top 10: 2 → 1 (-1)

63% less capital invested

Capital invested by funds: $2.64M → $965K (-$1.67M)

80% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 5

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
6
Holders Change
-4
Holders Change %
-40%
% of All Funds
0.14%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
1
Increased
–
Reduced
1
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$75.3K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$796K
2
SM
Sabby Management
Florida
-$731K
3
Renaissance Technologies
Renaissance Technologies
New York
-$71K
4
Citadel Advisors
Citadel Advisors
Florida
-$63K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$37.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
1
Sarissa Capital Management
Connecticut
$564K – – –
Vanguard Group
2
Vanguard Group
Pennsylvania
$127K -$37.6K -1 -25%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$89K +$75.3K +2 New
Franklin Resources
4
Franklin Resources
California
$41K – – –
HVC
5
Healthcare Value Capital
New Jersey
$39K – – –
BlackRock
6
BlackRock
New York
$33K – – –
VF
7
Virtu Financial
New York
$15K – – –
FDCDDQ
8
Federation des caisses Desjardins du Quebec
Quebec, Canada
$14.2K – – –
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$10K – – –
CS
10
Credit Suisse
Switzerland
$8K – – –
FWM
11
Frontier Wealth Management
Missouri
$8K – – –
Northern Trust
12
Northern Trust
Illinois
$6K – – –
CG
13
Colony Group
Massachusetts
$4K – – –
WP
14
WealthShield Partners
North Carolina
$4K – – –
FANJ
15
Financial Architects (New Jersey)
New Jersey
$1K – – –
LTFS
16
Ladenburg Thalmann Financial Services
Florida
$1K – – –
Morgan Stanley
17
Morgan Stanley
New York
$1K – – –
AC
18
Armistice Capital
New York
– -$796K -17 Closed
SM
19
Sabby Management
Florida
– -$731K -16 Closed
Renaissance Technologies
20
Renaissance Technologies
New York
– -$71K -2 Closed
Citadel Advisors
21
Citadel Advisors
Florida
– -$63K -1 Closed
Squarepoint
22
Squarepoint
New York
– -$29K -1 Closed
MML Investors Services
23
MML Investors Services
Massachusetts
– -$4K – –

SEEL Hedge Fund Activity: Q2 2018 in Review

6 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2018, worth a combined $965K — down 63% from $2.64M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of SEEL and 1 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Geode Capital Management, opening a new position worth an estimated $75.3K. The largest seller was Armistice Capital, exiting entirely with an estimated $796K sold.

  • 6 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2018, down from 10 in Q1 2018.
  • Funds reported $965K of Seelos Therapeutics, Inc. Common Stock stock for Q2 2018, down 63% quarter-over-quarter.
  • 1 fund opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2018 and 5 closed out, a net change of -4 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2018 was Geode Capital Management, an estimated $75.3K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2018 was Armistice Capital, an estimated $796K sold.

Based on aggregated 13F filings for Q2 2018.